The impaired apoE gene results in only 2-5% expression of apoE and a reduction in cholesterol homeostasis.

The disclosure provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299).

ApoE-4, a particular allele of the apolipoprotein apoE, is a known risk factor.

While every person inherits an APOE gene of some form, the APOE-e3 and APOE-e2 genes are not associated with Alzheimer's disease.

The invention provides gene-targeted non-human animals comprising a genetically modified apoE gene encodes a recombinant apoE polypeptide displaying domain interaction.

While every person inherits an APOE gene of some form, the APOE-e3 and APOE-e2 genes are not associated with Alzheimer's disease.

The present invention provides agents that reduce apoE-induced impairment of mitochondrial integrity and/or function; and use of such agents in the treatment of apoE-related disorders.

Alzheimer's: Targeting ApoE gene may 'stop the disease

A special case that could change everything about APOE

Disclosed is a method wherein the cholesterol in the HDL subfractions of ApoE-containing HDL-C and ApoE-deficient HDL-C, or in all HDL-C can be either separately or simultaneously quantified.

Antagonists that interfere with the ApoE-ApoER2 interaction are proposed for the treatment of AD.

Alzheimer's: Targeting ApoE gene may 'stop the disease

One group possessed the APOE ε4 gene and one did not.

However, carrying the APOE ε4 form of the gene does not necessarily mean that a person will develop Alzheimer’s disease, and people carrying no APOE ε4 can also develop the disease.

However, carrying the ApoE ε4 form of the gene does not necessarily mean that a person will develop Alzheimer’s disease, and people carrying no ApoE ε4 can also develop the disease.